The Role of Clinical Proteomics, Lipidomics, and Genomics in the Diagnosis of Alzheimer's Disease

Ian James Martins

*Edith Cowan University*
The Role of Clinical Proteomics, Lipidomics, and Genomics in the Diagnosis of Alzheimer’s Disease

Ian James Martins

School of Medical Sciences, Edith Cowan University, 270 Joondalup Drive, Joondalup 6027, Australia; i.martins@ecu.edu.au; Tel.: +61-8-6304-2574

Received: 5 February 2016; Accepted: 28 March 2016; Published: 31 March 2016

Abstract: The early diagnosis of Alzheimer’s disease (AD) has become important to the reversal and treatment of neurodegeneration, which may be relevant to premature brain aging that is associated with chronic disease progression. Clinical proteomics allows the detection of various proteins in fluids such as the urine, plasma, and cerebrospinal fluid for the diagnosis of AD. Interest in lipidomics has accelerated with plasma testing for various lipid biomarkers that may with clinical proteomics provide a more reproducible diagnosis for early brain aging that is connected to other chronic diseases. The combination of proteomics with lipidomics may decrease the biological variability between studies and provide reproducible results that detect a community’s susceptibility to AD. The diagnosis of chronic disease associated with AD that now involves genomics may provide increased sensitivity to avoid inadvertent errors related to plasma versus cerebrospinal fluid testing by proteomics and lipidomics that identify new disease biomarkers in body fluids, cells, and tissues. The diagnosis of AD by various plasma biomarkers with clinical proteomics may now require the involvement of lipidomics and genomics to provide interpretation of proteomic results from various laboratories around the world.

Keywords: diagnosis; biomarkers; Alzheimer’s disease; lipidomics; genomics; chronic disease; plasma; cerebrospinal fluid

1. Introduction

In the world approximately 44 million people have been diagnosed with Alzheimer’s disease (AD) or related dementia. The global cost of AD and dementia has now been estimated to be approx. $605 billion and is equivalent to 1% of the world’s gross domestic product. In the United States AD rates by age classifications are: 85+ years, 38%, 75–84 years, 44%, 65–74 years, 15%, <65 years, 4%. The age group under 65 years has been diagnosed with approx. 4% of the AD cases and as of 2016 the susceptibility to AD may have originated early in life with chronic diseases such as obesity, diabetes, and neurodegenerative diseases closely associated with hypothalamic disturbances and neurodegenerative diseases. AD is a neurodegenerative condition that involves disturbances in multiple higher brain functions including memory and cognition. Amyloid beta is the main constituent of AD senile plaques [1] and prevention of amyloidosis and dementia may require the diagnosis of individuals early in life to link chronic disease progression with early neurodegeneration.

In the current global epidemic the incidence of obesity and diabetes has been associated with non-alcoholic fatty liver disease (NAFLD) and insulin resistance, which in the developing and developed world may rise to between 30% and 40% of the global population [1,2]. Individuals homozygous for apo E4 develop AD but non-apo E4 individuals may also develop AD later in life, linked to chronic disease progression early in life involved in the induction of these AD cases (75–84 years, 44% AD cases). The association between chronic disease progression and AD indicates that clinical proteomics (Figure 1) may provide novel biomarkers with a serum protein profile that
may diagnose early progression to later-life AD. Plasma biomarkers such as amyloid beta have been an important diagnostic biomarker for AD but non-reproducible and insensitive results for amyloid beta have been obtained for the diagnosis of AD [3–5].

![CLINICAL PROTEOMICS Diagram]

**Figure 1.** In body fluids such as the urine, plasma, and cerebrospinal fluids, the abundance of proteins has become of importance in the diagnosis of various chronic diseases including Alzheimer’s disease. Testing of these fluids involves biological variation or differences in the sample along with inter- and intra-assay variability that may influence proteomics results. Measurement and data analysis of fluid proteomics can be improved by comparison with genomic and lipidomic data. Technological advances in Alzheimer’s disease (AD) allow interpretation of clinical proteomics, lipidomic, and genomic data that may assist in the development of new protein biomarkers with relevance to the reversal of chronic disease and the diagnosis of AD.

The cholesterol–AD connection [6] has attracted considerable interest with relevance to treatment with nutritional diets that maintain cell cholesterol homeostasis. The calorie-sensitive anti-aging gene Sirtuin 1 (Sirt 1) is closely involved in global disease progression with accelerated NAFLD, adiposity, and AD closely linked to Sirt 1 downregulation, hypercholesterolemia, and dementia [1,2]. Sirt 1 is one of the nuclear receptors that is known to regulate several cell functions by deacetylating both histone and non-histone targets. Sirt 1 is an NAD (+)-dependent class III histone deacetylase protein that targets transcription factors to adapt gene expression to metabolic activity, insulin resistance, and inflammation in chronic diseases. Dyslipidemia in AD has now become relevant to amyloidosis with tissue lipidomic analysis that indicates elevation in sphingolipids (sphingosine 1 phosphate) and ceramides in insulin-resistant and AD individuals [1]. Membrane cholesterol and sphingomyelin interactions are critical to amyloid beta oligomer formation with increased cellular ceramide levels associated with cholesterol displacement in membranes with relevance to amyloidosis and AD [7–9].

The interest in clinical lipidomics in AD has accelerated in recent years with relevance to early diagnosis by lipidomics of AD when compared with protein biomarker studies and may provide reproducible results for late MCI, prodromal disease, and dementia [10–12]. Analysis of a spectrum of plasma, tissue, or cerebrospinal fluid lipids (fatty acyls, glycerolipids, glycerophospholipids, sphingolipids, sterols, and prenols) assists in the diagnosis of various neurological diseases such as AD that are linked to chronic diseases in global populations [13–18]. Furthermore, new blood biomarker lipidomic panels have been identified with diagnostic value relevant to the preclinical and late stages of AD [19,20].

The global deterioration scale created by Reisberg provides the stages of cognitive function for those suffering from a primary degenerative dementia such as AD [11]. Stages 1–3 are the pre-dementia stages and stages 4–7 are the dementia stages. Lipidomic and genomic information have become
important to the diagnosis of the early stages [1–3] of AD (Figure 1), with abnormalities in cholesterol and lipoprotein metabolism [1] closely linked to the late progression of AD with changes in cognition or behavioral symptoms. Nutritional interventions for AD treatment and prevention in stages 1–3 have become important as the neuron disease that involves nuclear membrane changes induced by unhealthy diets and toxins is related to the corruption of the plasma and cerebrospinal fluid (CSF) dynamics, which may be reversible in early stages of the disease [21]. Plasma biomarker measurements by lipidomics and genomics (Figure 1) may provide more sensitive information compared with CSF measurements that may lead to erroneous diagnostic interpretations with lack of external quality assessment [22].

Information obtained from lipidomic and genomic analysis may provide information in relation to hepatic cholesterol metabolism, which is abnormal early in chronic disease and associated with neurodegeneration and biomarkers now relevant to diagnosis of early brain changes in individuals susceptible to AD. The use of lipidomic technology allows the study of the lipid composition of tissues such as the liver and brain that may determine the peripheral metabolism of cholesterol and amyloid beta that are important to the early stages of AD [23]. The brain–liver crosstalk is now central to the metabolism of amyloid beta, with the involvement of adipose tissue of relevance to hepatic amyloid beta metabolism [2]. Therefore, lipidomic and genomic tests for diagnosis of AD indicate that nuclear receptors are relevant to connections between insulin resistance, chronic disease, and AD. Downregulation of liver and brain cell nuclear receptors such as Sirt 1 in stages 1–3 of AD [11] is linked to chronic diseases (obesity/diabetes) and responsible for glucose, cholesterol, and amyloid beta metabolism disorders, which are abnormalities in the early stages of AD.

2. Multifactorial Nature of Alzheimer’s Disease Provides Important Links to Early Diagnosis

Proteomics has become important to the understanding of disease diagnosis with the apo E isoforms (apo E2, E3, and E4) related to the increased risk for AD [21]. Apo E4-related diseases have been shown to initiate toxic events that lead to synaptic dysfunction and neurodegeneration in AD [24]. The multifactorial nature of AD has raised concerns since apo E4 has also been shown to be involved in various other diseases such as insulin resistance, cardiovascular disease, hypercholesterolemia, obesity, and NAFLD [25–28]. Apo-E isoforms regulate Aβ aggregation and clearance in the liver and brain with effects of brain lipid transport, glucose metabolism, neuroinflammation, and mitochondrial function on amyloid beta transport [24]. The role of apo E4 in chronic disease progression is well understood but its role may be secondary compared to the primary role the anti-aging protein Sirt 1 has in nuclear receptor and transcriptional regulation involved with NAFLD, insulin resistance, mitochondrial function, neurodegeneration, cardiovascular disease, and AD [2,29–35]. Individuals with apo E3 have become of major concern for insulin resistance and NAFLD with links to AD [1,2] since NAFLD has risen to 30% of the global population and a lack of hepatic Sirt 1 activity relevant to the defect in the peripheral sink beta clearance pathway [23,36,37] associated with accelerated brain amyloidosis [36]. Diagnosis of early AD and neurological disease now involves clinical genomic cell analysis with Sirt 1 (Figure 2), transcriptional dysregulation [2,36,37] involved in appetite, and metabolic disease and obesity with relevance to hepatic amyloid beta, cholesterol, and glucose metabolism.

Clinical genomic testing (apo E) plays a major role in the diagnosis of AD and avoids inadvertent errors related to plasma versus CSF testing by proteomics and lipidomics that identify early and novel disease biomarkers in body fluids, cells, and tissues. Nutritional regulation of Sirt 1 in peripheral cells determines the peripheral clearance pathways for amyloid beta involving apolipoprotein E (apo E) and albumin [38,39]. Brain amyloid beta clearance [21,36] is secondary to nutritional regulation with the role of the liver Sirt 1 central and important to spontaneous brain alpha aggregation (oligomers and fibrils). Sirt 1 gene expression (Figure 2), especially its effects on transcriptional regulation and DNA methylation [2,35,40] in cells, has become of importance and may supersede apo E genotyping in cells for differential diagnosis of early AD.
Figure 2. Discovery of biomarkers that are consistent with the stages of development of AD and involve progression that includes mild cognitive impairment, prodromal disease, and the development of dementia. Proteomics that involve 10 plasma protein predictors (AD/dementia) and acute phase proteins (MCI/prodromal disease) allow detection of the severity of the stages of AD. Interest in genomics has accelerated with the identification of the calorie-sensitive gene Sirt 1, which may allow early AD diagnosis when compared to relevant proteomic/lipidomic biomarkers (ceramides, sphingolipids) that are involved in the later stages of AD. Interventions with nutritional therapy may activate cell Sirt 1/transcriptional regulation and maintain glucose, cholesterol, and amyloid beta levels connected to the delay in the progression and severity of AD (stages 4–7). Furthermore, multiple technologies may separate and diagnose individuals with other neurological disease from AD that may involve plasma, CSF, and tissue analysis.

Sirt 1 increases adiponectin transcription in adipocytes [2] by activation of forkhead transcription factor O1 (Foxo) interaction with CCAAT/enhancer-binding protein alpha (C/EBPalpha) to form a transcription complex at the mouse adiponectin promoter that upregulates adiponectin gene transcription [41]. Sirt 1 interactions with C/EBPalpha may involve Klotho C/EBPalpha and peroxisome proliferator-activated receptor (PPAR) interactions [2,42–44] with their important role in adipocyte differentiation. Dietary downregulation of Sirt 1 contributes to reduced adiponectin expression in obesity and diabetes [41] with effects on adipose tissue transformation and liver development [45]. Fibroblast growth factor 21 (FGF21) is an important activator of Sirt 1-mediated release of adiponectin [46]. FGF21 binds to FGF receptor and beta klotho receptor complex [47–51] and activates adipose tissue Sirt 1 by increases in NAD+ and activation of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1-alpha) and AMP-activated protein kinase (AMPK) [46,52]. Nutrition and PPAR alpha-Sirt 1 expression related to hepatic FGF21 production has become important to NAFLD and the metabolic syndrome [53–57]. FGF21 is regulated by fasting and feeding and with vasoactive intestinal peptide (VIP) associated with the circadian brain–liver amyloid beta clearance pathway [51,58–61] (Figure 3).
Liver FGF21 and adiponectin have been shown to regulate plasma apo B levels mediated via Sirt 1 and transcription factor C/EBPalpha, which regulates the amyloid beta metabolism and transport of amyloid beta across the blood–brain barrier [91,92] and is important to coronary events [90] and vascular effects in the central nervous system that determine peripheral intake [84,85] and sodium intake linked to adiponectin levels [86]. Sirt1's links to insulin resistance of neurons (Figure 3) [78–83]. Decreased VIP levels in plasma are associated with excess sodium intake [84,85] and low VIP levels, which contribute to coronary events [90] and vascular effects in the central nervous system, which determine hepatic amyloid beta metabolism and the regulation of apo E-mediated amyloid beta clearance pathways in the brain.

Low adiponectin levels and hypercholesterolemia with low high density lipoproteins (HDL) apolipoprotein AI levels and high low density lipoprotein (LDL) apolipoprotein B levels have been associated with insulin resistance and AD (Figure 3) [1]. Research into adiponectin and its regulation of ceramide metabolism (Figure 2) has shown that the effects on sphingolipid (sphingosine-1-phosphate) metabolism are connected to pancreatic insulin production [62–65]. Adiponectin deficiency has been shown to reduce hepatic ATP-binding cassette transporter ABCA1 (ABCA1) and apo AI synthesis with relevance to the reverse cholesterol transport [66]. Hepatic FGF21 has been shown to regulate lipolysis (fatty acid release) with FGF21 critical in the reduction of adipose tissue ceramides. In insulin resistance and AD, FGF21 and adiponectin levels are implicated in increased cellular ceramide levels associated with cholesterol displacement in membranes with relevance to amyloidosis and AD [7–9]. Sirt 1/adiponectin/FGF21 dysregulation determine hepatic cholesterol metabolism with effects on apo AI synthesis with relevance to hepatic lipid metabolism [68–71].

Sirt1 gene expression and its regulation early in life is central to hepatic glucose, cholesterol, and amyloid beta metabolism and their downregulation in stages 1–3 of AD (Figure 2) avoid errors with relevance to proteomic (adiponectin, FGF21) and lipidomic (ceramides, sphingolipids) analysis that may show increased or altered levels in plasma and CSF in later stages 4–7 of AD. Sirt 1’s role in circadian rhythms [72,73] and neuron survival is shown by connections to the circadian neuron regulation by the neuropeptide vasoactive intestinal peptide (VIP) [74–77] mediated via the activity-dependent neuroprotective protein (ADNP) release from astrocytes and the protection of neurons (Figure 3) [78–83]. Decreased VIP levels in plasma are associated with excess sodium intake [84,85] and sodium intake linked to adiponectin levels [86]. Sirt1’s links to insulin resistance (Figure 3) are associated with high plasma sodium levels [87–89] and low VIP levels, which contribute to coronary events [90] and vascular effects in the central nervous system that determine peripheral amyloid beta metabolism and transport of amyloid beta across the blood–brain barrier [91,92] and are
important to the role of VIP in the regulation of apo E-mediated amyloid beta clearance pathways in the brain and the liver [21,23,93].

Micro RNAs and neuron survival have become important, with micro RNA 34a (miR 34a), which inhibits Sirt 1, relevant to metabolic diseases and neurogenesis (Figure 3), possibly through interactions with hepatocyte nuclear factor (HNF4/HNF1 alpha (MODY gene), which may be relevant to the diagnosis of NAFLD and neurodegenerative diseases [2,94–96]. Interference of HNF4/PGC1 alpha by the transcription factor pregnane X receptor (PXR) is possibly connected to Sirt 1 regulation of PXR-mediated modulation of HNF4/PGC1 alpha, which is important for drug and cholesterol metabolism [18,97]. Sirt 1 deacetylation of the transcription factor p53 [2] mediates the effects of PXR with respect to HNF4/PGC1 alpha regulation [98,99] of hepatic cholesterol metabolism and amyloid beta metabolism, and also involves p53’s effects on VIP with ADNP release from neurons (Figure 3) [100]. Nutritional regulation and insulin resistance, which rely on miR 34a/Sirt 1 involvement in HNF-1/HNF4 interactions [101,102], are central to the links between the genetic regulation of diabetes and neurogenesis [36,96,103].

Interest in the field of proteomics has accelerated to determine the plasma biomarkers that provide increased sensitivity so as to avoid inadvertent errors related to plasma versus CSF markers for the reproducible diagnosis for AD. Biomarker studies that are consistent with the stages of development of specific brain changes in AD involve progression from no clinical manifestation to a prodromal stage with mild cognitive impairment and the development of final prodromal disease with dementia [10–12]. The plasma biomarkers involved in oxidative stress and inflammation that may be important to early diagnosis for AD (no clinical manifestation) are the hepatic acute phase reactants/cytokines (APP) involved in amyloid beta homeostasis with corruption of apo E-mediated cholesterol transport [21,23]. Acute phase proteins that directly interact with amyloid beta oligomers include serum amyloid protein P, serum amyloid protein A, alpha 2 macroglobulin, gelsolin, complement components, transthyretin, and clusterin [21]; these biomarkers assist with the early diagnosis of AD (Figure 2).

In a multiplexing approach a plasma protein panel has been identified to assess disease severity for predicting disease progression from prodromal disease to dementia. Ten proteins have been identified to diagnose AD [10]: include transthyretin, clusterin, cystatin C, alpha 1 acid glycoprotein, intercellular adhesion molecule 1, complement C4, pigment epithelium-derived factor, alpha 1 antitrypsin, RANTES, and apolipoprotein C3. These plasma protein biomarkers important to AD diagnosis overlap with CSF protein measurements in other neurological diseases [104–112]. Other novel proteomic candidate markers have been identified recently and promise to diagnose the very early and late stages of AD [113]. Furthermore, the activity-dependent neuroprotector homeobox protein has been shown to be downregulated in AD and may also be an important diagnostic marker for AD [81]. Proteomics that involve clinical biomarker discovery allow detection of severity for AD but the specific role of genomics such as cellular Sirt 1 may be to allow early diagnosis with Sirt 1 activation associated with relevant proteomic biomarkers (Figure 2) involved in the delay of the severity of disease progression from MCI to prodromal disease and dementia [114–119].

Nutritional research, involved in the activation of hepatic Sirt 1, which increases the low adiponectin levels associated with metabolic syndrome, platelet aggregation, and angiogenesis [119–123], is now required. Adiponectin has been shown to form protein complexes with alpha2-macroglobulin and thrombospondin-1 (TSP-1). Alterations in adiponectin levels determine alpha2–macroglobulin–amyloid beta interactions and TSP-1–amyloid beta interactions [124–127], which involve binding to cell receptors such as low-density lipoprotein receptor-related protein and heparin sulphate proteoglycans [128,129], showing a relationship between TSP-1 and amyloid beta in post-prandial lipid metabolism [37]. Adiponectin is important in astrocyte-neuron amyloid beta metabolism [1], with the effects of adiponectin on brain–liver amyloid clearance determined by proteins such as alpha 2 macroglobulin and TSP-1. TSP-1 is a matricellular protein involved in inflammation and in interactions with various proteins, platelet aggregation, and nitric oxide dyshomeostasis associated with cardiovascular disease, stroke, and diabetes [129–139]. TSP-1 is important to neuron
synaptogenesis, with astrocyte TSP-1 release [125] determined by brain adiponectin content with effects on astrocyte-neuron amyloid beta clearance [1]. Genomics and proteomics may assist in the early diagnosis of AD through the primary role of the gene Sirt1, adiponectin, and TSP-1 in amyloid beta homeostasis, while the corruption of liver and brain regulation has an effect on amyloid beta metabolism [21,23].

TSP-1 regulates transforming growth factor beta (TGF-β) levels with effects on TGF-β signaling, which determines TGF-β partitioning between lipid raft/caveolae- and clathrin-mediated endocytosis pathways [140–144]. Interactions between TSP-1 and TGF-β determine cell liver cholesterol (post-prandial lipid metabolism) [37] and peripheral amyloid beta homeostasis, which are relevant to chronic liver disease, NAFLD, atherogenesis, brain apoptosis, and AD [145–151]. The anti-aging protein GDF11, which belongs to the TGF-β family, has been shown to restore muscle and brain function [152,153], while the role of TSP-1 in the regulation of GDF11 needs to be determined.

3. **Nutriproteomic Diets Regulates Plasma Biomarkers and Reverses Neurodegeneration and Amyloidosis**

Clinical biomarker discoveries have become important with nutriproteomics [154–156] as a technology that could determine biomarkers that may assist with the maintenance of normal cognitive development in individuals at risk of AD. The ingestion of nutrients allows proteomic tools to characterize molecular and cellular changes in protein expression and function in the plasma and CSF [157–160] with respect to nutritional diets that activate the anti-aging gene Sirt1 and allow proteins such as amyloid beta/alpha synuclein to maintain monomer interactions and prevent self-association that induces inflammation [38,39]. Low-calorie diets (glucose, fatty acids) regulate Sirt1/adiponectin expression and nuclear interactions that involve nuclear receptors, transcription factors, and microRNAs that determine liver apo AI/apo B kinetics and ceramide metabolism with respect to amyloid beta metabolism in non-diabetic and diabetic individuals [161]. Integration of proteomics, lipidomics, and genomics technologies allows for the interpretation of various nutritional and dietary interventions that assist in the reversal of neurodegeneration in late MCI, prodromal disease, and dementia.

Nutritional research (low fat diets) that targets the intestine lowers the absorption of bacterial lipopolysaccharides (LPS) that have effects on acute inflammation, which involves lymphocytes, monocytes, and macrophages that stimulate tumor necrosis factor alpha (TNF-α) secretion from cells [162]. LPS induces NAFLD and insulin resistance, with insulin resistance linked to alterations in plasma/CSF sodium levels [163] (Figure 4). LPS alter apo E and amyloid beta interactions with accelerated amyloidosis [37,39,162,164] associated with biomarkers such as hepatic cytokines and APP-associated inhibition of reverse cholesterol transport [1,23]. Nutriproteomic diets, such as high fiber diets [6,135], have become important now that inflammatory regulation associated with LPS repression of Sirt1 [21,37] has been linked to atherogenic diets. Nutriproteomic diets such as very low carbohydrate diets maintain the circadian rhythm, brain–liver amyloid beta pathways, and sodium balance [165], reverse cholesterol transport involving adiponectin [86,166,167], and prevent cognitive decline, cardiovascular disease, and diabetes. These diets involve the measurements of plasma/CSF levels of adiponectin, FGF21, VIP, Klotho, IGF-1, TSP-1, TGF-beta, and gelsolin and may be relevant to healthy dietary interventions (Figure 4).
Interventions with nutriproteomic diets in individuals with MCI to prodromal disease and dementia may allow activation of Sirt 1/adiponectin expression with the identification of changes in plasma/CSF biomarkers (Figure 3) relevant to treatment of individuals with severe forms of prodromal dementia. Furthermore, high fat diets increase adipose tissue TSP-1 levels [168,169] and thus the risk for cardiovascular disease, neuron dysfunction, and defective NO pathways. Sirt 1 regulation of endothelial NOS has been reported with respect to neuroprotection and vascular-related diseases [170]. Diets that reduce TSP-1 improve adipose tissue apelin/Sirt 1 effects on nitric oxide disturbances and vasoconstriction [170]. Angiotensin II is critical to the regulation of TSP-1 disease and dementia. Furthermore, high fat diets increase adipose tissue TSP-1 levels [168,169] and affect toxic amyloid beta clearance pathways. LPS suppresses Sirt 1/adiponectin expression and increases TSP-1 release from cells with effects on adiponectin and peripheral amyloid beta/cholesterol clearance pathways. Nutritional therapy reduces LPS-induced inflammation and maintains hepatic TGF-β/cholesterol levels (apo AI, apo B); these nutriproteomic diets avoid the transfer of LPS/mycotoxin from the blood plasma to the CSF to prevent LPS/mycotoxin-induced brain apo E neutralization associated with the prevention of amyloidosis and neurodegeneration. Low calorie diets maintain plasma anti-aging protein GDF11, FGF21, VIP, gelsolin, insulin like growth factor 1 (IGF-1), and klotho levels, which are relevant to chronic diseases and AD.

Figure 4. Nutriproteomic diets as a treatment for cardiovascular disease, NAFLD, and AD activate hepatic Sirt 1 and increase hepatic FGF21 and VIP levels relevant to the maintenance of the hepatic peripheral amyloid beta clearance pathways. LPS suppresses Sirt 1/adiponectin expression and increases TSP-1 release from cells with effects on adiponectin and peripheral amyloid beta/cholesterol clearance pathways. Nutritional therapy reduces LPS-induced inflammation and maintains hepatic TGF-β/cholesterol levels (apo AI, apo B); these nutriproteomic diets avoid the transfer of LPS/mycotoxin from the blood plasma to the CSF to prevent LPS/mycotoxin-induced brain apo E neutralization associated with the prevention of amyloidosis and neurodegeneration. Low calorie diets maintain plasma anti-aging protein GDF11, FGF21, VIP, gelsolin, insulin like growth factor 1 (IGF-1), and klotho levels, which are relevant to chronic diseases and AD.
Diets that contain zinc may maintain Sirt 1 expression [21] and prevent abnormal LPS/zinc interactions. Zinc is sensitive to HNF4 [187] and reduced hepatic TNF-α toxicity [188,189] may aid the prevention of insulin resistance and AD [1]. Nutriproteomic diets as a treatment for reduction of LPS effects may lower TSP-1 expression by peripheral cells [190–192] and improve peripheral LPS–protein interactions [193–196] to accelerate peripheral amyloid beta metabolism with respect to treatment of individuals with prodromal disease and dementia. Nutritional diets that activate Sirt 1 and maintain therapeutic VIP and FGF21 levels [51] accelerate hepatic LPS/mycotoxin metabolism without transfer to the CSF and brain compartment [21], which is consistent with the use of nutritional therapy to maintain CSF composition, recycling, and amyloid beta dynamics [197,198] for the prevention of early neurodegeneration (stages 1–3) and amyloidosis.

4. Conclusions

The susceptibility to AD earlier in life may now involve chronic diseases such as obesity, diabetes, and neurodegenerative diseases. Nutritional interventions and early diagnosis may reduce spontaneous amyloid beta oligomerization associated with the excessive global cost ($605 billion) of late onset AD (>65 years). In the global crisis the inflammatory effects of LPS on apo E/Sirt 1 neutralization reaction induce increased TSP-1 levels that may be relevant to multifactorial diseases including cardiovascular diseases, NAFLD, and neurodegenerative diseases. Nutritional interventions are required to reduce the absorption of LPS early in life to prevent induction of inflammation linked to circadian abnormalities, accelerated amyloidosis metabolic disease, and neurodegeneration. Technologies of lipidomics, genomics, and proteomics are required to assess early plasma lipid and protein biomarkers that indicate repression of nuclear Sirt 1, which involves oxidative stress, inflammation associated with programmed cell death in chronic diseases, and early stages of AD (Reisberg). The genomic, lipidomic, and proteomic interpretation may provide evidence that apo E/Sirt 1 repression and liver disease in global populations is the major defect in early and late stages of MCI with links to prodromal disease and dementia.

Acknowledgments: This work was supported by grants from Edith Cowan University, the McCusker Alzheimer’s Research Foundation, and the National Health and Medical Research Council.

Conflicts of Interest: The author declares no conflict of interest.

References

1. Martins, I.J.; Creegan, R. Links between Insulin Resistance, Lipoprotein Metabolism and Amyloidosis in Alzheimer’s Disease. Health 2014, 6, 1549–1579. [CrossRef]


45. Westmacott, A.; Burke, Z.D.; Oliver, G.; Slack, J.M.; Tosh, D. C/EBPα and C/EBPβ are markers of early liver development. *Int. J. Dev. Biol.* 2006, 50, 653–657. [CrossRef] [PubMed]


79. Gozes, I.; Divinsky, I.; Pilzer, I.; Fridkin, M.; Brenneman, D.E.; Spier, A.D. From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: A view of neuroprotection and cell division. J. Mol. Neurosci. 2003, 20, 315–322. [CrossRef]


103. Ellard, S. Hepatocyte nuclear factor 1 alpha (HNF1 alpha) mutations in maturity-onset diabetes of the young. *Hum. Mutat.* 2000, 16, 377–385. [CrossRef]


110. Pearl, G.S.; Mullins, R.E. Alpha 1-antitrypsin in cerebrospinal fluid of patients with neurologic diseases. *Arch. Neurol.* 1985, 42, 775–777. [CrossRef] [PubMed]


© 2016 by the author; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).